Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3368-3377

  Isaacs, Claudine ^a   Robert, Nicholas J ^a   Bailey, F Amos ^a   Schuster, Michael W ^a   Overmoyer, Beth ^a   Graham, Mark ^a   Cai, Bin ^a   Beach, Kathleen J ^a   Loewy, John W ^a   Kaye, James A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0030666621     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3368     Document Type: Article

References (49)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988
2. Clark G, Sledge GW Jr, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55-61, 1987
3. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
4. Sledge GW, Antman KH: Progress in chemotherapy for metastatic breast cancer. Semin Oncol 19:317-333, 1992
5. O'Shaughnessy JA, Cowan KH: Dose-intensive therapy for breast cancer. JAMA 270:2089-2092, 1993
6. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
7. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
8. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
9. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
10. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
11. Lichtman SM, Ratain MJ, Van Echo DA, et al: Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: A Cancer and Leukemia Group B Study. J Natl Cancer Inst 85:1319-1326, 1993
12. Mamounas EP, Anderson S, Wickerham DL, et al: The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. Am J Clin Oncol 17:374-381, 1994
13. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
14. Bissett D, Jodrell D, Harnett AN, et al: Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support. Br J Cancer 71:1279-1282, 1995
15. Wallace EL, Churchill WH, Surgenor DM, et al: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 35:802-812, 1995
16. Collins C, Livingston RB, Ellis G, et al: Effect of PIXY321 on hematologic recovery after high-dose cyclophosphamide (CTX), etoposide (VP-16) and cisplatin (CDDP) (CEP) in women with breast carcinoma. Blood 82:366, 1993 (suppl 1, abstr)
17. Williams DE, Farese A, MacVittie TJ: PIXY321, but not GM-CSF plus IL-3, promotes hematopoietic reconstitution following lethal irradiation. Blood 82:366, 1993 (suppl 1, abstr)
18. Demetri GD, Bukowski RM, Samuels B, et al: Stimulation of thrombopoiesis by recombinant human interleukin-6 (IL-6) pre-and post-chemotherapy in previously untreated sarcoma patients with normal hematopoiesis. Blood 82:367, 1993 (suppl 1, abstr)
19. Crawford J, Figlin R, Chang A, et al: Phase I/II trial of recombinant human interleukin-6 (rhIL-6) and granulocyte colony stimulating factor (rhG-CSF) following ifosphamide, carboplatin and etoposide (ICE) chemotherapy in patients with advanced non-small cell lung carcinoma (NSCLC). Blood 82:367, 1993 (suppl 1, abstr)
20. Veldhuis GJ, Willemse PHB, Sleijfer DT, et al: Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13:2585-2593, 1995
21. Schulz G, Krumwieh D, Oster W: Adjuvant therapy with recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. Pharmacol Ther 52:85-94, 1991
22. Tepler I, Elias L, Smith JW II, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996
23. Musashi M, Yang Y-C, Paul SR, et al: Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 88:765-769, 1991
24. Musashi M, Clark SC, Sudo T, et al: Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78:1448-1451, 1991
25. Teramura M, Kobayashi S, Hoshino S, et al: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327-331, 1992
26. Weich N, Wang A, Fitzgerald M, et al: Interleukin-11 receptor expression in megakaryocytes. Blood 88:60a, 1996 (suppl 1, abstr)
27. Weich NS, Neben TY, Donaldson D, et al: Effects of interleu-kin-11 on megakaryocytopoiesis are direct. Eur Cytokine Netw 7:601, 1996 (abstr)
28. Kaviani MD, Mason LE, Bree AG, et al: Effects of recombinant human interleukin 11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates. Blood 88:26a, 1996 (suppl 1, abstr)
29. Swain SM, Rowland J, Weinfurt K, et al: Intensive outpatient adjuvant therapy for breast cancer: Results of dose escalation and quality of life. J Clin Oncol 14:1565-1572, 1996
30. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al: A phase 1 trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 87:3615-3624, 1996
31. Pisciotto PT, Benson K, Hume H, et al: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498-502, 1995
32. O'Shaughnessy JA, Venzon DJ, Gossard M, et al: A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 86:2913-2921, 1995
33. Basser RL, Rasko JEJ, Clarke K, et al: Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348:1279-1281, 1996
34. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409, 1997
35. Ault KA, Mitchell J, Knowles C, et al: Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects. Blood 84:276a, 1994 (suppl 1, abstr)
36. Dykstra K, Rogge H, Stone A, et al: Effect of diuretic treatment on rhIL-11-induced salt and water retention. Blood 88:346a, 1996 (suppl 1, abstr)
37. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
38. Dunphy FR, Spitzer G: Use of very-high-dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 84:128-129, 1992
39. Patrone F, Ballestrero A, Ferrando F, et al: Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 13:840-846, 1995
40. Somlo G, Doroshow JH, Forman SJ, et al: High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 73:1678-1685, 1994
41. Kritz A, Crown JP, Motzer RJ, et al: Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. Cancer 71:2515-2521, 1993
42. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
43. Pico JL, Ibrahim A, Castagna L, et al: Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology 50:47-52, 1993 (suppl 2)
44. Zoubek A, Holzinger B, Mann G, et al: High-dose cyclophosphamide, Adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor. Pediatr Hematol Oncol 11:613-623, 1994
45. Shpall EJ, Jones RB, Bearman SI, et al: Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol Oncol 54:357-361, 1994
46. Benedetti-Panici P, Greggi S, Scambia G, et al: Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 31A: 1987-1992, 1995
47. de Vries EG, de Graaf H, Boonstra A, et al: High-dose chemotherapy with stem cell reinfusion and growth factor support for solid tumors. Stem Cells 13:597-606, 1995
48. Aviles A, Nambo MJ, Talavera A, et al: GM-CSF instead of hematological support during high-dose chemotherapy for refractory malignant lymphoma. Leuk Lymphoma 17:327-330, 1995
49. Norton L: Salvage chemotherapy of breast cancer. Semin Oncol 21:19-24, 1994 (suppl 7)